Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE

Neuroscience Letters

Volumn 531, Issue 1, 2012, Pages 35-39

  Hu, Xianzhen ^a   Tomlinson, Stephen ^b,c   Barnum, Scott R ^a,d  

^a University of Alabama at Birmingham   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Autoimmune disease; Experimental autoimmune encephalomyelitis; Immunology; Neuroimmunology complement

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR 2 FACTOR H INHIBITOR; COMPLEMENT RECEPTOR 2 INHIBITOR; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS;

EID: 84869092488     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.10.012     Document Type: Article

References (50)

1. Atkinson C., Qiao F., Song H., Gilkeson G.S., Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. Journal of Immunology 2008, 180:1231-1238.
2. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., Tsokos G.C., Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. The Journal of Clinical Investigation 2005, 115:2444-2453.
3. Banda N.K., Levitt B., Glogowska M.J., Thurman J.M., Takahashi K., Stahl G.L., Tomlinson S., Arend W.P., Holers V.M. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. Journal of Immunology 2009, 183:5928-5937.
4. Barnum S.R., Szalai A.J. Complement and demyelinating disease: no MAC needed?. Brain Research Reviews 2006, 52:58-68.
5. Brodsky R.A. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Reviews 2008, 22:65-74.
6. Brodsky R.A., Young N.S., Antonioli E., Risitano A.M., Schrezenmeier H., Schubert J., Gaya A., Coyle L., de Castro C., Fu C.L., Maciejewski J.P., Bessler M., Kroon H.A., Rother R.P., Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111:1840-1847.
7. Buck D., Hemmer B. Treatment of multiple sclerosis: current concepts and future perspectives. Journal of Neurology 2011, 258:1747-1762.
8. Bullard D.C., Hu X., Adams J.E., Schoeb T.R., Barnum S.R. p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. The American Journal of Pathology 2007, 170:2001-2008.
9. Bullard D.C., Hu X., Schoeb T.R., Axtell R.C., Raman C., Barnum S.R. Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. Journal of Immunology 2005, 175:6327-6333.
10. Compston A. McAlpine's Multiple Sclerosis 2006, Elsevier/Churchill Livingstone, Philadelphia.
11. Davoust N., Nataf S., Reiman R., Holers M.V., Campbell I.L., Barnum S.R. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. Journal of Immunology 1999, 163:6551-6556.
12. Elvington A., Atkinson C., Kulik L., Zhu H., Yu J., Kindy M.S., Holers V.M., Tomlinson S. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. Journal of Immunology 2012, 188:1460-1468.
13. Flachenecker P., Stuke K. National MS registries. Journal of Neurology 2008, 255(Suppl. 6):102-108.
14. Gold L., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain: A Journal of Neurology 2006, 129:1953-1971.
15. Hawker K. Progressive multiple sclerosis: characteristics and management. Neurologic Clinics 2011, 29:423-434.
16. Holers V.M., Thurman J.M. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Molecular Immunology 2004, 41:147-152.
17. Huang Y., Qiao F., Atkinson C., Holers V.M., Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. Journal of Immunology 2008, 181:8068-8076.
18. Jain N., Bhatti M.T. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012, 78:672-680.
19. Kieseier B.C., Stuve O. A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nature Reviews Neurology 2011, 7:255-262.
20. Kleinschmidt-Demasters B.K., Miravalle A., Schowinsky J., Corboy J., Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. Journal of Neuropathology and Experimental Neurology 2012, 71:604-617.
21. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. The New England Journal of Medicine 2005, 353:369-374.
22. Lambris J.D., Holers V.M. Therapeutic Interventions in the Complement System 2000, Humana Press, Totowa, 259 pp.
23. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. The New England Journal of Medicine 2005, 353:375-381.
24. Levine S., Cochrane C.G., Carpenter C.B., Behan P.O. Allergic encephalomyelitis: effect of complement depletion with cobra venom. Proceedings of the Society for Experimental Biology and Medicine 1971, 138:285-289.
25. Linington C., Morgan B.P., Scolding N.J., Wilkins P., Piddlesden S., Compston D.A. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain: A Journal of Neurology 1989, 112:895-911.
26. Lumsden C.E. The immunogenesis of the multiple sclerosis plaque. Brain Research 1970, 28:365-390.
27. Morariu M.A., Dalmasso A.P. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Annals of Neurology 1978, 4:427-430.
28. Morgan B.P., Harris C.L. Complement Regulatory Proteins 1999, vol. 1. Academic Press, San Diego, 382 pp.
29. Morgan B.P., Harris C.L. Complement therapeutics; history and current progress. Molecular Immunology 2003, 40:159-170.
30. Nataf S., Carroll S.L., Wetsel R.A., Szalai A.J., Barnum S.R. Attenuation of experimental autoimmune demyelination in complement-deficient mice. Journal of Immunology 2000, 165:5867-5873.
31. Oldstone M.B., Dixon F.J. Immunohistochemical study of allergic encephalomyelitis. The American Journal of Pathology 1968, 52:251-263.
32. Pabst H., Day N.K., Gewurz H., Good R.A. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proceedings of the Society for Experimental Biology and Medicine 1971, 136:555-560.
33. Paidassi H., Tacnet-Delorme P., Arlaud G.J., Frachet P. How phagocytes track down and respond to apoptotic cells. Critical Reviews in Immunology 2009, 29:111-130.
34. Pelletier D., Hafler D.A. Fingolimod for multiple sclerosis. The New England Journal of Medicine 2012, 366:339-347.
35. Piddlesden S., Lassmann H., Laffafian I., Morgan B.P., Linington C. Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clinical and Experimental Immunology 1991, 83:245-250.
36. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. Journal of Immunology 1994, 152:5477-5484.
37. Qiao F., Atkinson C., Song H., Pannu R., Singh I., Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. The American Journal of Pathology 2006, 169:1039-1047.
38. Ransohoff R.M. Natalizumab and PML. Nature Neuroscience 2005, 8:1275.
39. Reynolds R., Roncaroli F., Nicholas R., Radotra B., Gveric D., Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathologica 2011, 122:155-170.
40. Rohrer B., Long Q., Coughlin B., Wilson R.B., Huang Y., Qiao F., Tang P.H., Kunchithapautham K., Gilkeson G.S., Tomlinson S. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Investigative Ophthalmology and Visual Science 2009, 50:3056-3064.
41. Saidha S., Eckstein C., Calabresi P.A. New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciences 2012, 1247:117-137.
42. Schepp-Berglind J., Atkinson C., Elvington M., Qiao F., Mannon P., Tomlinson S. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. Journal of Immunology 2012, 188:6309-6318.
43. Song H., He C., Knaak C., Guthridge J.M., Holers V.M., Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. The Journal of Clinical Investigation 2003, 111:1875-1885.
44. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Annals of Neurology 2006, 60:12-21.
45. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends in Immunology 2005, 26:565-571.
46. Szalai A.J., Hu X., Adams J.E., Barnum S.R. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Molecular Immunology 2007, 44:3132-3136.
47. Szalai A.J., Nataf S., Hu X.Z., Barnum S.R. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. Journal of Immunology 2002, 168:5792-5797.
48. van Kooten C., Fiore N., Trouw L.A., Csomor E., Xu W., Castellano G., Daha M.R., Gelderman K.A. Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. Molecular Immunology 2008, 45:4064-4072.
49. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Reviews Immunology 2002, 2:85-95.
50. Weber M.S., Menge T., Lehmann-Horn K., Kronsbein H.C., Zettl U., Sellner J., Hemmer B., Stuve O. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Current Pharmaceutical Design 2012, 18:209-219.